Anti-RNase L – Purified in vivo PLATINUM™ Functional Grade

Based on the search results, there are multiple different antibody clones designated "2E9" that target different proteins, so the specific in vivo applications depend on which 2E9 clone you're referring to.

Pig SLA Class II DR Antibody (Clone 2E9/13)

The most detailed information available is for the mouse anti-pig SLA Class II DR antibody, clone 2E9/13. However, this antibody is specifically designed to recognize porcine (pig) antigens, not mouse antigens, so it would not be suitable for standard in vivo mouse studies. This clone recognizes SLA DR molecules expressed on B cells, antigen presenting cells, and certain T cell subsets in pigs, and has been reported to inhibit mixed lymphocyte reactions and T cell stimulation.

Other 2E9 Clones

The search results also reference other antibodies with the 2E9 designation that target different proteins:

• Anti-RNase L clone 2E9: A mouse monoclonal antibody that detects 2-5A-dependent ribonuclease
• Anti-Amyloid beta A4 protein clone 2E9: A rat monoclonal antibody targeting amyloid beta A4 protein
• Anti-LAT clone 2E9: Validated for immunoprecipitation and Western blotting applications

In Vivo Dosing Considerations

While specific dosing information for 2E9 clones wasn't provided, the search results do include general guidance for in vivo antibody studies in mice. For comparison, other antibody clones used in mouse studies typically use doses ranging from 100-250 ?g per mouse via intraperitoneal injection, with dosing schedules every 3 days.

Without more specific information about which 2E9 clone and target protein you're interested in, it's difficult to provide detailed in vivo protocols. The specific application, dosing, and administration route would depend entirely on the target antigen and experimental objectives.

Based on the product information provided, the sterile packaged clone 2E9 (SLA Class II DR Monoclonal Antibody) has specific storage temperature requirements.

Short-term Storage

For short-term storage, the antibody should be stored at 4°C. This temperature is suitable when you plan to use the antibody within a relatively short period.

Long-term Storage

For long-term storage, the antibody should be stored at -20°C. This lower temperature provides better stability for extended storage periods while maintaining the antibody's functionality.

Important Storage Considerations

When storing this antibody, it's crucial to avoid freeze/thaw cycles. Repeated freezing and thawing can damage the antibody structure and reduce its binding capacity. To prevent this, consider dividing the antibody into small aliquots so you only thaw what you need for each experiment.

The storage recommendations for this specific clone align with general monoclonal antibody storage principles, where most antibodies remain stable at -20°C and can retain their binding capacity for years when properly stored. The key is maintaining consistent temperatures and avoiding temperature fluctuations that could compromise the antibody's integrity.

Commonly used antibodies or proteins used alongside 2E9 in the literature depend on the specific target and experimental context. The designation "2E9" applies to distinct antibodies targeting different proteins, but two prominent examples are:

1. Tau Antibody (2E9) Context

When 2E9 refers to an anti-Tau antibody (commonly used in neurobiology and Alzheimer's disease research), these antibodies are often used in combination with:

• Other Tau antibodies: To distinguish between different Tau isoforms, total Tau, or specific post-translational modifications such as phosphorylation. Examples include Tau-5, Tau-12, Tau-13, SP70, D1M9X, and 43D, which detect different epitopes or modified forms of Tau.

• Cytoskeleton-associated proteins: Such as anti-alpha internexin, which labels intermediate filaments, and anti-MAP2, which labels dendritic markers for neuronal cell identification and structural visualization.

• Nuclear stains: Such as DAPI or DNA-specific dyes, used to visualize cell nuclei in immunofluorescence experiments.

• Loading controls or reference proteins: Used in Western blotting (e.g., ?-actin, GAPDH) to normalize protein expression levels across samples.

Experimental Example:

"E18 primary rat hippocampal neurons ... immunostained with 2E9 (green), chicken antibody to alpha internexin (red) and for DNA (blue)."

2. Other Contexts for 2E9

a. 2E9 as Anti-SLA Class II DR (Pig MHC) Antibody:

• Often used with antibodies against:
  • Other swine leukocyte antigen (SLA) class II proteins (such as SLA-DP, SLA-DQ).
  • T cell and B cell markers, especially when delineating immune cell subsets in pigs.

b. 2E9 as a Control Antibody:

• In protein aggregation studies (e.g., myocilin misfolding in glaucoma research), 2E9 is mentioned as a control antibody and is commonly used alongside:
  • Anti-OLF1 and anti-OLF2 antibodies, which target different domains of the myocilin protein.

Summary Table: Commonly Paired Antibodies/Proteins with 2E9

Key insight:
The specific antibodies used with 2E9 depend on its application (e.g., anti-Tau, anti-pig MHC II, generic control), but commonly paired antibodies include other epitope- or PTM-specific antibodies against the same protein, cytoskeletal markers, and nuclear stains. Always verify the particular 2E9 variant and application in the original literature to select the most relevant companion reagents.

Clone 2E9 has been extensively studied across different scientific applications, with key findings spanning neurological disease research and infectious disease immunotherapy. The research demonstrates this clone's versatility and significant therapeutic potential.

Neurodegenerative Disease Research

Clone 2E9 has shown exceptional promise in the development of monoclonal antibodies targeting phosphorylated TDP-43 protein, which is crucial for understanding frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The clone demonstrated high immunoreactivity in multiple screening assays, including ELISA and dot blot analyses, confirming its specificity for pS409/410-TDP-43. This specificity is particularly important because TDP-43 inclusions are pathological hallmarks of FTD and ALS.

In comparative studies, 2E9 showed stronger immunoactivity to GFP-TDP-25 than other clones (23H11 and 23A8), indicating superior binding characteristics. The clone successfully detected cytoplasmic TDP-43 in immunohistochemistry analyses and demonstrated the ability to detect TDP-43 pathology in FTLD-TDP patient brain tissue. Based on these comprehensive results, 2E9 was selected as one of three promising B cell clones (along with 26H10 and 23A1) for generating rabbit monoclonal antibodies.

Tuberculosis Immunotherapy Research

In infectious disease applications, clone 2E9 has been developed into a novel human IgA1 monoclonal antibody with significant protective properties against tuberculosis infection. The antibody demonstrated high binding affinities for both the mycobacterial ?-crystallin antigen and the human Fc?RI (CD89) IgA receptor.

Protective Efficacy Results:

• Intranasal inoculations with 2E9IgA1 combined with recombinant mouse IFN-? significantly inhibited pulmonary H37Rv tuberculosis infection in mice transgenic for human CD89
• The protection was CD89-dependent, as no protective effects were observed in CD89-negative littermate controls
• Combined treatment with IFN-? plus 2E9IgA1 achieved the lowest bacterial counts (4.33 × 10^4 geometric mean CFU) compared to controls (4.67 × 10^5 CFU)

Screening and Validation Methodology

The research established 2E9 as a benchmark for antibody screening workflows. The clone consistently performed well across multiple validation steps, including primary ELISA screening, secondary biochemical assays, and tertiary specificity testing with phosphorylation-resistant constructs. This reliability made it an excellent model for demonstrating effective B cell clone screening methodologies.

The findings from clone 2E9 research have contributed significantly to both the understanding of neurodegenerative disease mechanisms and the development of novel immunotherapeutic approaches for infectious diseases, establishing it as a valuable research tool with translational potential.